Rights and permissions
About this article
Cite this article
NICE no longer recommends omalizumab for asthma . . .. Pharmacoecon. Outcomes News 667, 14 (2012). https://doi.org/10.2165/00151234-201206670-00029
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201206670-00029